InVivo Therapeutics (NVIVQ) 10-K2016 FY Annual report

Filed: 10 Mar 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: absence, abuse, affirming, Affordable, Agriculture, aim, al, arm, attestation, avoiding, axon, axonal, bioresearch, Brexit, broadly, Canadian, category, CDER, central, Century, certiorari, cervical, choose, clarify, clock, Cohort, compliant, complicating, compound, comprehensive, concealing, Congressional, conspiracy, constrain, consumption, Contemporary, convention, conventional, core, CRISPR, deadline, defamation, defective, Deferral, defraud, demyelinated, denominated, department, disapproval, disapproved, disorder, dispense, docket, dosing, Dossier, driven, Dutch, economic, electorate, electromyography, EmployerIdentification, EU, EUDAMED, European, evidencing, exit, feature, feedback, formula, fraudulent, gene, guide, Hampshire, hemicordectomy, Hillsborough, HIPAA, hopeful, Imaging, Immunofluorescence, imprisonment, inactive, incurrence, indirectly, input, insignificant, internationally, intrinsic, invoiced, issuable, ITA, IVDR, Kingdom, knowingly, laminin, launched, liable, linguistic, lowest, MDD, Medicaid, Medicare, migrate, modular, module, municipal, myelination, NDA, nearest, NOL, nonemployee, opposition, overhead, pace, page, paper, Parliament, passed, penumbra, persist, petition, pharmacological, PHSA, Physician, play, Portability, pp, preempted, prescription, promulgated, QUALITATIVE, quantify, QUANTITATIVE, qui, randomized, referendum, reform, regime, regimen, regrowth, reintroduced, relationship, remuneration, remyelinating, renewed, repeal, repealed, reprice, reprocessing, Resonance, restructuring, retrospectively, reward, role, rolling, sacral, safeguarding, ScaffoldTM, scheme, Schwann, screen, scrutiny, sequestration, Similarly, single, sought, Southern, standalone, strain, sublease, subtenant, Sunshine, Supreme, tam, Taxpayer, teaching, text, textual, thereunder, today, toxicological, Trademark, TrailMaker, TrailMakerTM, transmission, transparency, treble, tubulin, UDI, unrealized, unused, unwilling, Vitro, voluntarily, Welfare, whistleblower, willfully, withholding, writ, wrong

Removed: absolute, began, borrowing, Bronson, circumvented, collusion, conceived, decimal, drew, EMG, error, execute, faulty, fourth, hemisection, inInternal, Lavik, Lawrence, merger, mistake, Ourednik, override, Park, preferred, Qu, redemption, revalued, simple, Snyder, tendered, Woodard, Yu, Zurakowski

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NVIVQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES‑OXLEY ACT OF 2002

In connection with the Annual Report of InVivo Therapeutics Holdings Corp. (the “Company”) on Form 10‑K for the year ended December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mark D. Perrin, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Dated: March 10, 2017	/s/ Mark D. Perrin
	Mark D. Perrin
	Chief Executive Officer
	(Principal Executive Officer)